DOTA- beta- Ala(3)- Nle(4)- Asp(5)- Phe(7)- Lys(10)- (111)indium-alpha-MSH (3-10)

structure in first source

Also Known As:

(111)indium-alpha-MSH (3-10), DOTA-beta-Ala(3)-Nle(4)-Asp(5)-Phe(7)-Lys(10)-; 111In-DOTA-3-beta-Ala-4-Nle-5-Asp-7-Phe-10-Lys-alpha-MHS(3-10); 111In-alpha-MSH (3-10)-DOTA-beta-alanyl(3)-norleucyl(4)-aspartyl(5)-phenylalanyl(7)-lysyl(10)-; DOTA-MSH(oct)

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Eberle, Alex N: 3 articles (09/2003 - 12/2002)
2.	Froidevaux, Sylvie: 3 articles (09/2003 - 12/2002)
3.	Calame-Christe, Martine: 2 articles (06/2003 - 12/2002)
4.	Sumanovski, Lazar: 2 articles (06/2003 - 12/2002)
5.	Tanner, Heidi: 2 articles (06/2003 - 12/2002)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2003 - "In vivo, [(111)In]DOTA-MSH(OCT) exhibited a favorable biodistribution profile after injection in B16-F1 tumor-bearing mice. " 12/01/2002 - "Therefore, (111)In-DOTA-MSH(oct) displayed higher uptake ratios of tumor to nontarget tissue (e.g., tumor-to-bone ratio 4 h after injection was 4.9 for (111)In-DOTA-NDP-MSH and 53.9 for (111)In-DOTA-MSH(oct)). "
2.	Neoplasm Metastasis (Metastasis) 09/01/2003 - "Lung and liver melanoma metastases could be clearly imaged on tissue section autoradiographs 4 h after injection of [(111)In]DOTA-MSH(OCT). " 06/01/2003 - "Lung and liver melanoma metastases could be clearly imaged on tissue section autoradiographs 4 h after injection of [(111)In]DOTA-MSH(OCT). " 09/01/2003 - "These results demonstrate that [(111)In]DOTA-MSH(OCT) specifically targets melanoma metastases and represents a lead compound for the development of therapeutic DOTA-MSH analogs."
3.	Melanoma (Melanoma, Malignant) 06/01/2003 - "These results demonstrate that [(111)In]DOTA-MSH(OCT) is a promising melanoma imaging agent." 09/01/2003 - "Lung and liver melanoma metastases could be clearly imaged on tissue section autoradiographs 4 h after injection of [(111)In]DOTA-MSH(OCT). " 06/01/2003 - "Lung and liver melanoma metastases could be clearly imaged on tissue section autoradiographs 4 h after injection of [(111)In]DOTA-MSH(OCT). " 09/01/2003 - "These results demonstrate that [(111)In]DOTA-MSH(OCT) specifically targets melanoma metastases and represents a lead compound for the development of therapeutic DOTA-MSH analogs."

Related Drugs and Biologics

1.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
2.	Melanocyte-Stimulating Hormones (MSH)
3.	4-Nle-7-Phe-alpha- MSH